OakChart

Cellectis ADR

CLLSHealthcare·Biotechnology·France·Micro·NASD·Nov 11 • 8:49 AM ET

1.27+0.16 (14.41%)
2026-11-11 14:52 CET
Market cap
80.28 USD m
Revenue, TTM
56.42 USD m
Net income, TTM
-65.33 USD m
Free cash flow, TTM
-44.18 USD m
EPS diluted, TTM
-0.65
P/E
-
Compare

Price

CLLS against its 20, 50 and 200-day averages
2050200beat
1.002.003.004.00589K1.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CLLSclose 1.2720-day 1.0750-day 1.53200-day 2.951.27

76.7% under 5.45 on 11 Dec 2025. Last 15 sessions, 47.1% high to low

Profile

CLLS
52-week range, 9% of the way up
0.885.45

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.

Employees229
IPOMar 25, 2015
Beta3.17
ATR, 14d0.13
Rel volume12.72
Short float0.48%
Insider own3.93%
Inst own13.18%

Snapshot

6 groups

Valuation

Index-
Market Cap91.86M
Enterprise Value29.29M
Income-65.33M
Sales56.42M
Book/sh0.41
Cash/sh2.31
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees229
IPOMar 25, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S1.63
P/B3.11
P/C0.55
P/FCF-
EV/EBITDA-
EV/Sales0.52
Quick Ratio1.37
Current Ratio1.37
Debt/Eq2.54
LT Debt/Eq2.19
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.65
EPS next Y-0.67
EPS next Q-0.18
EPS this Y-19.90%
EPS next Y17.01%
EPS next 5Y-26.03%
EPS past 3/5Y33.81% 18.84%
Sales past 3/5Y56.25% -0.34%
EPS Y/Y TTM-13.99%
Sales Y/Y TTM-0.11%
EPS Q/Q9.72%
Sales Q/Q-69.19%
EarningsAug 06 AMC
EPS/Sales Surpr.16.35% -37.52%

Ownership

Insider Own3.93%
Insider Trans0.00%
Inst Own13.18%
Inst Trans0.20%
ROA-21.03%
ROE-94.56%
ROIC-49.84%
Gross Margin66.25%
Oper. Margin-116.10%
Profit Margin-115.79%
SMA2018.66%
SMA50-16.77%
SMA200-56.90%
Trades-

Technical

Shs Outstand100.70M
Shs Float69.48M
Short Float0.48%
Short Ratio3.16
Short Interest0.33M
52W High5.45 -76.70%
52W Low0.88 44.19%
Volatility11.51% 10.02%
ATR (14)0.13
RSI (14)52.30
Beta3.17
Rel Volume12.72
Avg Volume105.23K
Volume66,909

Performance

Perf Week8.55%
Perf Month15.45%
Perf Quarter-60.06%
Perf Half Y-68.09%
Perf YTD-73.76%
Perf Year-65.86%
Perf 3Y-49.40%
Perf 5Y-87.72%
Perf 10Y-93.36%
Recom2.29
Target Price5.00
Prev Close1.11
Price1.27
Change %14.41%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 16, 2026DowngradeBBarclaysOverweight → Underweight$1.30+2.4%
Sep 15, 2026DowngradeCCitizensMkt Outperform → Mkt Perform
May 28, 2026InitiatedBBarclaysOverweight$9+608.7%
Feb 17, 2026ResumedJJefferiesBuy$7+451.2%
Mar 17, 2023InitiatedBBryan GarnierBuy$6+372.4%
May 18, 2022UpgradeRRobert W. BairdNeutral → Outperform$10+687.4%
Jan 06, 2022DowngradeWWells FargoOverweight → Equal Weight$39 → $16+1,159.8%
Nov 30, 2021InitiatedJJMP SecuritiesMkt Outperform$20+1,474.8%
Nov 08, 2021DowngradeWWilliam BlairOutperform → Mkt Perform
Oct 08, 2021DowngradeRRobert W. BairdOutperform → Neutral$39 → $10+687.4%

Peers

Mkt cap
TickerCompanyMkt cap
CRBUCaribou Biosciences Inc43.22M
ALLOAllogene Therapeutics Inc332.57M
ATRAAtara Biotherapeutics Inc81.31M
CRSPCRISPR Therapeutics AG4.47B
DTILPrecision Biosciences Inc263.99M
IPSCCentury Therapeutics Inc304.21M
SANASana Biotechnology Inc728.56M
FATEFate Therapeutics Inc220.04M
NKTXNkarta Inc108.27M
AUTLAutolus Therapeutics plc ADR353.59M

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.47B

News

latest 14 of 206
  • Cellectis to Report Third Quarter Financial Results on November 12, 2026 (GlobeNewswire)
  • Monthly information on share capital and company voting rights (GlobeNewswire) +7.34% -11.97%
  • Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 (GlobeNewswire) +8.64%
  • Monthly information on share capital and company voting rights (GlobeNewswire)
  • Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls (The Fly) -14.60%
  • Loading…
  • Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls (The Fly) -12.02%
  • CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot (Stocktwits)
  • Cellectis Announces In Vivo Gene Editing Transformation, Exits Lasme-cel and Eti-cel Development (InvestorsHub) -40.97%
  • Cellectis quits CAR-Ts and pivots to in vivo gene editing (BioPharma Dive)
  • Cellectis quits CAR-T and pivots to in vivo gene editing (BioPharma Dive)
  • Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company (GlobeNewswire)
  • Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update (GlobeNewswire)
  • Monthly information on share capital and company voting rights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-06-0.220-0.263-0.2206.9011.056
2026Q12026-05-11-0.180-0.258-0.1777.5511.046
2025Q42026-03-19-0.260-0.203-0.26212.1613.396
2025Q32025-11-070.010-0.2320.00637.169.556
2025Q22025-08-04-0.240-0.214-0.24018.1911.235
2025Q12025-05-12-0.180-0.154-0.18112.0313.835
2024Q42025-03-13-0.170-0.1850.08233.229.866
2024Q32024-11-04-0.230-0.203-0.23118.059.776
2024Q22024-08-06-0.280-0.287-0.2529.503.707
2024Q12024-05-280.080-0.3300.0556.503.705
2023Q42024-04-29-0.640-0.195-0.6021.991.803
2023Q32023-11-06-0.310-0.418-0.3131.643.388
2023Q22023-08-03-0.190-0.438-0.1912.004.487
2023Q12023-05-04-0.580-0.481-0.5873.565.997
2022Q42023-03-08-0.590-0.596-0.59317.3218.589
2022Q32022-11-03-0.630-0.446-0.6221.9216.888

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.410-2.471-2.40522.9922.63
2020FY-1.910-2.189-1.92082.4662.04
2021FY-2.550-3.063-2.54467.0761.20
2022FY-2.330-2.300-2.33225.7332.85
2023FY-1.770-1.184-1.7759.1930.44
2024FY-0.410-0.633-0.40549.2241.51
2025FY-0.671-0.757-0.67179.6077.35
2026FY--0.803--53.56
2027FY--0.667--85.32
2028FY--1.341--73.48
2029FY--1.050--92.73
2030FY--0.630--161.31

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2140015.6110.0019.60
2026Q3S2026-09-1841015.6110.0019.60
2026Q3S2026-08-0751115.1910.0019.60
2026Q3S2026-07-2640015.107.5519.60
2026Q3S2026-06-2840115.107.5519.60
2026Q3S2026-06-0360113.677.5519.60
2026Q3S2026-05-1260213.677.5519.60
2026Q3S2026-03-2060214.7910.0019.60
2026Q3S2026-02-1350017.6012.8022.06
2026Q3S2026-01-2440017.1012.8022.06
2026Q3S2025-12-3041017.1012.8022.06
2026Q3S2025-11-1141117.1012.8022.06
2026Q3S2025-11-1041117.1012.8022.06
2026Q3S2025-11-0920112.659.5015.80

Estimate history

EPS, annual-2.813-1.928-2.405-1.92-2.544-2.332-1.775-0.405-0.676-0.6502
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.252-0.2310.082-0.181-0.240.006-0.262-0.177-0.217
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual25.44812.71715.18774.43930.29919.1820.75641.43273.17556.42
Period201720182019202020212022202320242025TTM
Sales, quarterly8.05316.24612.62610.66316.94935.01310.3895.7985.222
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual35.95542.4342.46642.7845.48445.67671.751100.094100.339100.698
Period201720182019202020212022202320242025MRQ
Shares, quarterly100.094100.094100.094100.29100.325100.325100.339100.602100.698
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue56.4273.1741.430.7619.1830.3074.4415.1912.72
Cost of Goods Sold Incl. D&A19.0420.1219.8419.2518.5215.9736.5211.392.74
Gross Profit37.3853.0521.59-18.500.6614.3237.923.809.98
Selling, General and Administrative Excl. Other102.8993.5389.5988.2998.31125.88132.32135.03123.68
Research and Development82.9575.0872.0287.7897.55117.6687.5392.0276.48
Other Operating Expense0.000.000.000.00-0.000.00--
Operating Income-65.51-40.48-68.00-106.79-97.65-111.56-94.40-131.24-113.70
Interest Expense8.418.137.486.4416.344.363.652.960.72
Unusual Expense7.4814.32-11.6220.600.000.000.00--
Net Income Before Taxes-72.92-74.89-43.13-123.24-105.20-104.82-106.62-122.99-96.79
Income Taxes-7.59-7.09-6.44-6.22-6.46-8.23-8.49-7.80-8.55
Consolidated Net Income-65.33-67.80-36.70-117.02-98.74-96.60-98.13-115.19-88.24
Net Income From Continuing Operations-65.33-67.80-36.70-109.62-90.84-85.70-81.61-102.07-78.61
Net Income-65.33-67.80-36.70-101.22-106.20-114.02-81.61-102.07-78.61
EPS (Recurring)-0.60-0.58-0.50-1.52-2.33-2.54-1.92-2.40-1.93
EPS (Basic, Before Extraordinaries)-0.65-0.68-0.41-1.78-2.33-2.54-1.92-2.40-1.93
EPS (Diluted)-0.65-0.68-0.41-1.78-2.33-2.54-1.92-2.40-1.93
EBITDA-46.46-20.36-48.16-88.24-79.20-97.42-84.51-124.36-111.33
Non-Operating Income (Expense)8.47-11.9620.7210.598.7911.09-8.5711.2117.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.984.602.373.854.448.2612.1318.5437.18
Price To Sales Ratio5.356.633.93232.224.9912.0115.4547.8453.38
Gross Margin66.2572.5052.12-2,446.233.4447.2850.9525.0078.49
Operating Margin-116.10-55.32-164.12-14,122.65-509.08-368.18-126.81-864.13-894.06
Net Margin-115.79-92.66-88.57-13,385.30-553.64-376.30-109.64-672.09-618.12
Shares Outstanding100.70100.34100.0971.7545.6845.4842.7842.4742.43
Market Capitalization80.2880.28129.77220.9995.50369.261,149.76726.67701.06

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue5.225.8010.3935.0116.9510.6612.6316.25
Cost of Goods Sold Incl. D&A4.414.555.104.995.084.935.794.73
Gross Profit0.821.255.2930.0311.865.736.8411.51
Selling, General and Administrative Excl. Other26.2728.3524.1224.1623.4521.7219.8324.35
Research and Development20.8923.0919.6219.3418.6717.3715.3623.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-25.45-27.10-18.835.87-11.59-15.99-12.99-12.83
Interest Expense2.012.272.032.102.081.911.712.15
Unusual Expense-2.25-6.098.797.030.29-1.87-1.223.83
Net Income Before Taxes-23.44-19.56-28.53-1.40-25.58-19.485.11-25.00
Income Taxes-1.65-1.73-2.23-1.98-1.53-1.34-0.77-1.88
Consolidated Net Income-21.79-17.83-26.300.59-24.05-18.145.88-23.12
Net Income From Continuing Operations-21.79-17.83-26.300.59-24.05-18.145.88-23.12
Net Income-21.79-17.83-26.300.59-24.05-18.145.88-23.12
EPS (Recurring)-0.23-0.22-0.200.05-0.24-0.190.07-0.20
EPS (Basic, Before Extraordinaries)-0.22-0.18-0.260.01-0.24-0.180.08-0.23
EPS (Diluted)-0.22-0.18-0.260.01-0.24-0.180.08-0.23
EBITDA-21.04-22.55-13.7310.86-6.50-11.06-7.20-8.10
Non-Operating Income (Expense)1.773.721.121.86-11.62-3.4418.59-6.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.711.391.691.200.970.730.660.43
Price To Sales Ratio5.354.686.653.852.712.613.137.29
Gross Margin15.6221.5050.9285.7670.0053.7354.1670.86
Operating Margin-487.40-467.39-181.2216.76-68.36-149.97-102.88-78.99
Net Margin-417.27-307.51-253.131.67-141.92-170.1446.57-142.32
Shares Outstanding100.70100.60100.34100.33100.33100.29100.09100.09
Market Capitalization80.28229.27485.57205.47109.9489.40129.77152.84

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments208.66260.31203.8197.70186.13268.24360.91451.89296.98
Short Term Receivables25.3223.0423.1317.5731.0719.1915.2922.0714.69
Inventories0.000.000.000.000.001.612.900.280.25
Other Current Assets2.263.736.066.778.2226.3212.4213.4111.30
Total Current Assets236.24287.07233.00122.04225.43315.36391.52487.64323.22
Net Property, Plant & Equipment62.4575.8692.74107.90148.27145.5269.3210.047.23
Total Investments and Advances3.295.427.858.796.527.015.521.891.00
Long-Term Note Receivable1.802.10-------
Intangible Assets0.541.120.670.721.851.581.111.271.43
Deferred Tax Assets7.149.39-------
Other Assets20.0211.590.0021.770.000.000.000.000.00
Total Assets331.48392.55334.27261.22382.08469.47467.47500.84332.88
Short Term Debt Incl. Current Port. of LT Debt18.1624.5213.6612.8410.586.701.070.330.02
Accounts Payable17.2818.6619.0721.4623.7624.6129.2615.889.46
Other Current Liabilities110.31123.09122.4113.8315.0120.7132.2730.6535.97
Total Current Liabilities145.75166.27155.1448.1349.3552.0262.6046.8745.45
Long Term Debt101.7485.1379.1962.9390.3099.9846.541.020.01
Provision for Risks Charges1.331.112.202.394.074.012.852.683.43
Deferred Tax Liabilities6.769.010.16------
Other Liabilities0.000.0012.8821.831.894.620.000.000.00
Total Liabilities255.58261.52249.57135.28145.60160.62112.0050.5748.90
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity75.90131.0384.69117.97221.29275.57315.12409.30264.87
Total Shareholders Equity75.90131.0384.69117.97221.29275.57315.12409.30264.87
Accumulated Minority Interest0.000.000.007.9715.1833.2740.3540.9719.11
Total Equity75.90131.0384.69125.94236.47308.85355.47450.27283.98
Total Liabilities & Stockholders Equity331.48392.55334.27261.22382.08469.47467.47500.84332.88
Book Value Per Share0.761.311.182.584.876.447.429.657.37
Tangible Book Value Per Share0.751.301.172.574.826.407.399.627.33
Full-Time Employees229222221237294281264171135
Price to Book Ratio2.721.392.250.701.674.202.311.733.70
Return on Assets-18.73-10.10-36.82-28.24-20.13-17.42-21.08-18.86-30.22
Return on Equity-65.53-34.02-108.18-53.55-34.50-27.63-28.18-23.25-37.33
Return on Invested Capital-38.17-16.98-61.76-58.71-36.59-21.73-28.22-19.16-37.90
Quick Ratio1.621.731.502.544.576.036.2110.407.11
Current Ratio1.621.731.502.544.576.066.2510.407.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-65.23-67.80-36.70-108.61-114.10-124.91-98.13-115.19-88.24
Depreciation19.0520.1219.8118.5518.4514.139.886.872.37
Other Funds (Non Cash)20.5249.26-14.5816.0113.5518.2929.4227.5426.89
Funds from Operations-25.661.58-31.47-74.05-82.10-92.49-58.82-80.78-58.98
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-16.34-41.7253.5748.93-5.73-12.28-21.9711.65-9.09
Cash from Operating Activities-42.00-40.1422.10-25.12-87.82-104.77-80.79-69.13-68.06
Capital Expenditures-3.36-3.54-3.84-1.07-2.44-18.53-46.57-12.96-4.88
Net Assets From Acquisitions0.000.000.00-1.640.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.050.411.26
Purchase or Sale of Investments35.22-26.03-98.79-12.890.1314.83-8.19-23.3239.20
Purchase of Investments-115.88-160.27-162.48-13.380.00-0.14-8.19-23.32-
Sale Or Maturity of Investments151.11134.2463.690.490.1314.98--39.20
Other Uses0.000.000.000.00-0.450.000.000.000.00
Other Sources0.000.000.000.080.0010.960.000.00-
Cash from Investing Activities31.87-29.58-102.63-15.53-2.767.27-54.70-35.8735.58
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.250.0482.6868.04-0.5756.159.82-0.47236.37
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.470.00
Sale of Common Pref Stock0.250.0482.6868.04-0.5756.159.820.00236.37
Proceedsfrom Stock Options0.250.0482.6868.04-0.5756.159.270.00236.37
Issuance or Reduction of Debt, Net--5.4018.1724.604.410.0024.330.00-0.13
Change in Long Term Debt-------0.000.00
Issuance of Long Term Debt-------0.000.00
Reduction of Long Term Debt-------0.000.00
Net Financing Active Other Cash Flow0.000.000.001.788.652.290.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-16.10-16.2089.8083.331.4847.8227.50-3.86236.24
Exchange Rate Effect2.413.94-2.750.89-3.36-5.747.96-2.10-8.85
Net Change in Cash-23.83-81.976.5343.56-92.47-55.43-100.03-110.96194.91
Free Cash Flow-44.18-42.5019.52-26.19-90.26-123.28-126.79-82.04-72.77
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--8.35------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments166.85185.66208.66192.22198.15243.69
Short Term Receivables13.6415.0525.3226.4129.3725.52
Inventories0.000.000.000.000.000.00
Other Current Assets3.933.842.262.563.122.61
Total Current Assets184.42204.55236.24221.19230.64271.82
Net Property, Plant & Equipment53.9957.9362.4566.7170.1772.93
Total Investments and Advances4.723.843.2935.7435.494.33
Intangible Assets1.120.220.540.841.150.24
Deferred Tax Assets0.380.387.140.380.380.38
Other Assets22.7322.2620.0218.1816.1314.37
Total Assets267.37289.19331.48343.05353.97364.09
Short Term Debt Incl. Current Port. of LT Debt14.2715.1618.1626.5725.7124.65
Accounts Payable18.2017.0917.2816.1017.5217.21
Other Current Liabilities102.48102.25110.31105.91124.20120.71
Total Current Liabilities134.96134.50145.75148.58167.43162.57
Long Term Debt90.0193.44101.7492.6588.1284.17
Provision for Risks Charges1.331.321.331.341.301.14
Deferred Tax Liabilities--6.76---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities226.30229.27255.58242.57256.86247.88
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity41.0759.9275.90100.4897.11116.20
Total Shareholders Equity41.0759.9275.90100.4897.11116.20
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity41.0759.9275.90100.4897.11116.20
Total Liabilities & Stockholders Equity267.37289.19331.48343.05353.97364.09
Book Value Per Share0.410.600.761.000.971.16
Tangible Book Value Per Share0.400.590.750.990.961.16
Full-Time Employees--229---
Price to Book Ratio2.724.194.832.941.320.95
Return on Assets-21.03-20.69-18.76-9.67-15.62-16.88
Return on Equity-94.56-76.76-65.63-31.08-48.38-58.64
Return on Invested Capital-16.62-11.63-14.800.30-12.99-9.05
Quick Ratio1.371.521.621.491.381.67
Current Ratio1.371.521.621.491.381.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-21.79-17.83-26.360.75-24.07-18.13
Depreciation4.404.555.104.995.104.93
Other Funds (Non Cash)1.95-2.8912.129.3420.707.10
Funds from Operations-15.44-16.17-9.1415.091.73-6.09
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.090.61-1.34-16.71-12.45-11.22
Cash from Operating Activities-14.34-15.56-10.47-1.63-10.72-17.31
Capital Expenditures-0.25-0.27-0.49-2.35-0.31-0.40
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments19.00-5.9223.06-0.92-52.794.62
Purchase of Investments-27.70-78.28-7.06-2.85-145.33-5.04
Sale Or Maturity of Investments46.7072.3630.121.9392.549.65
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities18.75-6.1922.57-3.27-53.114.22
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.170.030.040.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.170.030.040.000.000.00
Proceedsfrom Stock Options0.170.030.040.000.000.00
Issuance or Reduction of Debt, Net-1.39-1.40-1.39-1.38-1.37-1.25
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-3.16-4.83-4.03-4.09-4.14-3.94
Exchange Rate Effect-0.43-0.221.341.71-0.521.41
Net Change in Cash0.82-26.799.41-7.27-68.50-15.62
Free Cash Flow-14.59-15.82-10.95-2.81-11.04-17.71
Price to Free Cash Flow-----4.85

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 41.51M 2025: 72.95M
France2024: 41.51M 2025: 72.95M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.48%0.3M69.5M104.80K
2026-10-150.46%0.3M69.5M85.11K
2026-09-300.51%0.4M69.5M74.74K
2026-09-150.70%0.5M69.5M52.02K
2026-08-310.42%0.3M69.5M27.72K
2026-08-140.43%0.3M69.5M31.27K
2026-07-310.43%0.3M69.5M31.15K
2026-07-150.42%0.3M69.5M33.35K
2026-06-300.46%0.3M69.5M39.24K
2026-06-150.53%0.4M69.5M39.55K
2026-05-290.51%0.4M69.5M40.89K
2026-05-150.49%0.3M69.5M39.06K
2026-04-300.52%0.4M69.5M43.03K
2026-04-150.55%0.4M69.5M45.28K
2026-03-310.52%0.4M69.5M45.31K
2026-03-130.50%0.4M69.5M59.07K
2026-02-270.56%0.4M69.5M66.56K
2026-02-130.57%0.4M69.5M90.47K
2026-01-300.57%0.4M69.5M95.44K
2026-01-150.60%0.4M69.5M121.12K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.552.6010.7031.000.000.686-0.0340.001
call5.000.004.200.2513.43115.000.000.663-0.0450.001
call7.500.002.600.0014.2290.000.000.648-0.0490.001
put2.500.004.200.550.0001.000.00-0.311-0.0370.001
put5.003.804.202.0010.11411.000.00-0.337-0.0450.001
put7.504.409.000.000.0000.000.00-0.348-0.0490.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-09SCHEDULE 13D/ASEC
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-116-K/A2026-06-30SEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-11SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-30SEC
2026-06-266-K/A2026-06-26SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-11SEC
2026-06-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-09SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-20SEC
2026-05-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-20SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC
2026-05-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-11SEC
2026-05-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-11SEC
2026-05-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-04SEC
2026-04-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-27SEC
2026-04-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-13SEC
2026-03-2020-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-19SEC
2026-03-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-12SEC
2026-01-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-08SEC
2025-12-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-15SEC
2025-12-12SCHEDULE 13D/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
B Group, Inc.4.54%
Long Focus Capital Management, LLC3.79%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3.66%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.0.31%
BlackRock, Inc.0.31%
LPL Financial LLC0.12%
MORGAN STANLEY0.12%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.07%
UBS Group AG0.07%
BNP PARIBAS FINANCIAL MARKETS0.06%

Funds

Fund% owned
Nomura Healthcare Fund0.31%
iShares Biotechnology ETF0.31%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. CLLS. Cached 15 minutes.

Some panels did not load: insider.